{"analyses":[{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.13","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.65","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.32","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.06","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.007","statisticalMethod":"Wilcoxon signed rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"136","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"KSHV viral load in peripheral blood mononuclear cells was assessed by modifying a sandwich enzyme-linked immunosorbent assay (ELISA). Viral load testing may provide useful information on the occurrence of KSHV replication. Undetectable levels is good.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Baseline to 4 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG000","title":"Baseline to 4 Weeks"},{"description":"Baseline to 8 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG001","title":"Baseline to 8 Weeks"},{"description":"Baseline to end of treatment for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG002","title":"Baseline to End of Treatment"}],"paramType":"MEDIAN","populationDescription":"PBMC = peripheral mononuclear cells","reportingStatus":"POSTED","timeFrame":"Baseline to 4 weeks, baseline to 8 weeks and baseline to end of treatment","title":"Change Between Timepoints Baseline to 4 Weeks, Baseline to 8 Weeks, and Baseline to End of Treatment in Kaposi Sarcoma-Associated Herpesvirus (KSHV) Viral Load","type":"SECONDARY","unitOfMeasure":"copies per million PBMC"}